Dasgupta, Suryasarathi and Navarrete, Ana-Maria and Delignat, Sandrine and Wootla, Bharath and Andre, Sebastien and Nagaraja, Valakunja and Lacroix-Desmazes, Sebastien and Kaveri, Srinivas V (2007) Immune response against therapeutic factor VIII in hemophilia A patients—A survey of probable risk factors. In: Immunology Letters, 110 (1). pp. 23-28.
Restricted to Registered users only
Download (365Kb) | Request a copy
A number of diseases are treated by passive administration of human proteins. Human coagulation factor VIII (FVIII) is one such protein which is adminsitered to hemophilia A patients in order to manage and treat hemorrhagic incidences. This mode of therapy suffers from the side effect of generating anti-FVIII antibodies (inhibitors) which neutralizes the function of the infused FVIII. At a time when efficient viral screening procedures are at place, development of inhibitors poses the greatest threat to such a therapy. Various predisposing factors, both patient and product-related, are responsible for the development of inhibitory antibodies. A proper understanding of these “risk-factors” would eventually help to better design therapeutic regimen to tackle hemophilia A.
|Item Type:||Journal Article|
|Additional Information:||Copyright of this article belongs to Elsevier.|
|Keywords:||Factor VIII;Hemophilia;Inhibitors;Risk factors|
|Department/Centre:||Division of Biological Sciences > Microbiology & Cell Biology|
|Date Deposited:||15 Oct 2007|
|Last Modified:||19 Sep 2010 04:39|
Actions (login required)